| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ACE2 |
| Uniprot No | Q9BYF1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 18-615aa |
| 氨基酸序列 | QSTIEEQAKT FLDKFNHEAE DLFYQSSLAS WNYNTNITEE NVQNMNNAGD KWSAFLKEQS TLAQMYPLQE IQNLTVKLQL QALQQNGSSV LSEDKSKRLN TILNTMSTIY STGKVCNPDN PQECLLLEPG LNEIMANSLD YNERLWAWES WRSEVGKQLR PLYEEYVVLK NEMARANHYE DYGDYWRGDY EVNGVDGYDY SRGQLIEDVE HTFEEIKPLY EHLHAYVRAK LMNAYPSYIS PIGCLPAHLL GDMWGRFWTN LYSLTVPFGQ KPNIDVTDAM VDQAWDAQRI FKEAEKFFVS VGLPNMTQGF WENSMLTDPG NVQKAVCHPT AWDLGKGDFR ILMCTKVTMD DFLTAHHEMG HIQYDMAYAA QPFLLRNGAN EGFHEAVGEI MSLSAATPKH LKSIGLLSPD FQEDNETEIN FLLKQALTIV GTLPFTYMLE KWRWMVFKGE IPKDQWMKKW WEMKREIVGV VEPVPHDETY CDPASLFHVS NDYSFIRYYT RTLYQFQFQE ALCQAAKHEG PLHKCDISNS TEAGQKLFNM LRLGKSEPWT LALENVVGAK NMNVRPLLNY FEPLFTWLKD QNKNSFVGWS TDWSPYADGG GGSGGGGSDK THTCPPCPAP EAAGGPSVFL FPPKPKDTLM ISRTPEVTCV VVDVSHEDPE VKFNWYVDGV EVHNAKTKPR EEQYNSTYRV VSVLTVLHQD WLNGKEYKCK VSNKALPAPI EKTISKAKGQ PREPQVYTLP PSRDELTKNQ VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPVLDSDG SFFLYSKLTV DKSRWQQGNV FSCSVMHEAL HNHYTQKSLS LSPGK |
| 预测分子量 | 190 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ACE2重组蛋白的3篇代表性文献(示例为模拟生成，非真实文献)：
1. **"Structural and functional analysis of recombinant human ACE2 as a SARS-CoV-2 receptor"**
- 作者：Hua, A. et al.
- 摘要：通过X射线晶体学解析了重组人ACE2蛋白的分子结构，揭示了其与SARS-CoV-2刺突蛋白的结合位点，证实ACE2重组蛋白可有效阻断病毒入侵宿主细胞的机制。
2. **"Engineered soluble ACE2 protein therapy mitigates COVID-19 lung injury in primate models"**
- 作者：Li, L. et al.
- 摘要：研究报道了一种工程化重组可溶性ACE2蛋白，在非人灵长类模型中显著降低SARS-CoV-2病毒载量并缓解急性肺损伤，提示其作为COVID-19治疗药物的潜力。
3. **"High-yield production of recombinant ACE2 in mammalian cells for antiviral screening"**
- 作者：Zhang, Y. et al.
- 摘要：开发了一种基于HEK293细胞的高效重组ACE2蛋白表达系统，验证其与多种冠状病毒的结合能力，为抗病毒药物筛选提供标准化工具。
4. **"ACE2-Fc fusion protein extends half-life and enhances neutralization against SARS-CoV-2 variants"**
- 作者：Wang, Q. et al.
- 摘要：通过将重组ACE2与IgG Fc片段融合，显著延长其体内半衰期，并证明该融合蛋白对多种新冠变异株具有广谱中和活性。
(注：以上内容为模拟生成，实际文献需通过PubMed或Google Scholar查询。)
Angiotensin-converting enzyme 2 (ACE2) is a membrane-bound protein that plays a critical role in the renin-angiotensin system (RAS), regulating blood pressure, fluid balance, and vascular health. It counterbalances ACE by converting angiotensin II (a vasoconstrictor) into angiotensin-(1-7), a vasodilator with anti-inflammatory and cardioprotective effects. Beyond its physiological functions, ACE2 gained significant attention as the primary receptor for SARS-CoV-2. the virus responsible for COVID-19. enabling viral entry into host cells via spike protein interaction.
Recombinant ACE2 proteins are engineered versions of the extracellular domain of ACE2. produced using expression systems like mammalian cells (e.g., HEK293) or bacteria. These proteins retain the receptor-binding capability and enzymatic activity of native ACE2. Research focuses on their dual therapeutic potential: (1) as decoy receptors to neutralize SARS-CoV-2 by competitively binding viral spikes, reducing infection, and (2) as modulators of RAS to treat conditions like acute respiratory distress syndrome (ARDS) or cardiovascular diseases.
In diagnostics, recombinant ACE2 serves as a tool to study virus-host interactions, screen neutralizing antibodies, or develop antiviral drugs. However, challenges remain, including optimizing protein stability, glycosylation patterns (critical for viral binding), and scalability. Recent studies also explore soluble ACE2 fusion proteins or nanoparticles to enhance therapeutic efficacy. Despite promising preclinical results, clinical applications require further validation of safety, pharmacokinetics, and long-term effects. Overall, recombinant ACE2 represents a versatile biomolecule bridging virology, immunology, and precision medicine.
×
